Immune Resetting: B-Cell Mediated & Beyond Summit is redefining the conversation around immune modulation and therapeutic innovation. As the global biopharma industry accelerates its focus on autoimmune and inflammatory diseases, this summit provides an exclusive platform for uncovering the next wave of breakthroughs in B-cell biology and beyond.

The event brings together leading immunologists, clinical researchers, and pharma executives to explore how precision targeting of B-cell pathways is transforming treatment paradigms. From novel mechanisms of immune resetting to advanced biologics and cell-based strategies, attendees will gain unparalleled insights into the science driving durable responses and improved patient outcomes.

Connect with experts from Cabaletta Bio, GentiBio, Kite Pharma, FAU, Cullian Therapeutics, Kali Therapeutics, University of Pittsburgh, Bristol Myers Squibb, Oblenio Bio, and more.

Beyond the science, the summit addresses critical challenges in translating these innovations into the clinic, covering biomarker development, regulatory considerations, and scalable manufacturing solutions. With autoimmune disorders and chronic inflammation representing multi-billion-dollar markets, the discussions will highlight how emerging therapies can meet unmet needs and unlock new commercial opportunities.

Expect deep dives into cutting-edge research, candid conversations on investment trends, and strategic perspectives from industry leaders shaping the next generation of immune-modulating therapies.

Join the summit to discover how immune resetting is not just a scientific milestone but a transformative force in global healthcare, positioning biopharma at the forefront of innovation and patient-centric solutions.

See what the current attendees are looking forward to:

“I look forward to hearing and seeing the latest developments in immune resetting and meeting with a diverse group of researchers in this field. I am also excited to present Hinge’s GEM-DIMER molecule, HB2198, for depletion of CD19/CD20 expressing B cells.”

Senior Director – Preclinical Development, Hinge Bio 

“I am interested to share our observations for B-cell depletion and reconstitution in Rese-cel treated individuals and hear what others have seen in their trials.”

Principal Scientist, Cabaletta Bio